Syneron Medical Ltd

Type: Company
Name: Syneron Medical Ltd
First reported 1 hour ago - Updated 1 hour ago - 2 reports

Syneron Receives US FDA Clearance to Market the UltraShape System for Fat Cell Destruction

MEDIA RELEASE PR56573 IRVINE, California, Apr. 24, 2014 /PRNewswire-AsiaNet/ -- -- Positions Syneron with Disruptive Product Offering in Fast Growing Body Contouring and Fat Treatment MarketSyneron Medical Ltd. (NASDAQ: ELOS), a global market leader in ... [Published Medianet - 1 hour ago]
First reported 7 hours ago - Updated 7 hours ago - 1 reports

Syneron Medical Stock Rating Lowered by Zacks (ELOS)

Separately, analysts at Leerink Swann raised their price target on shares of Syneron Medical to $17.00 in a research note on Monday, February 3rd.Shares of Syneron Medical (NASDAQ:ELOS) traded up 1.56% on Wednesday, hitting $11.04. 59,704 shares of the ... [Published American Banking News - Stock Ratings - 7 hours ago]
First reported Apr 22 2014 - Updated Apr 22 2014 - 2 reports

ABIOMED Up on License from Opsens

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.Leading provider of heart support technologies, ... [Published Zacks.com - Apr 22 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Syneron Medical's CEO Discusses FDA Clearance of the UltraShape System - Conference Call Transcript

Syneron Medical Ltd., ( ELOS ) FDA Clearance of the UltraShape System Conference Call April 17, 2014 8:30 AM ETOperatorGood day, ladies and gentlemen and welcome to the Syneron Medical Ltd., Conference Event. At this time, all participants are in a listen-only ... [Published Seeking Alpha - Apr 17 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 3 reports

Syneron to Host Conference Call and Webcast to Discuss UltraShape FDA Clearance

IRVINE, Calif.The conference call and webcast will be hosted by Syneron management and will take place at 8:30 am ETInvestors and analysts may participate in the conference call and question & answer session using the following dial-in numbers:US (toll ... [Published Benzinga.com - Apr 16 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 2 reports

The New Wave in Covidien's Endoscopic Devices - Analyst Blog

Irish medical device giant Covidien plc ( COV ) recently acquired Florida-based New Wave Surgical for more than $100 million. Shares of Covidien rose 1.3% in the trading session following the news release and closed at $69.92 yesterday.New Wave Surgical's ... [Published Nasdaq - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 15 2014 - 3 reports

BioTime, Inc. Announces Board Membership Changes and Management and Board Changes at Its Subsidiary Asterias Biotherapeutics, Inc.

ALAMEDA, Calif.--(EON: Enhanced Online News)--BioTime, Inc. (NYSE MKT: BTX) announced that its Board of Directors has appointed Deborah Andrews and David Schlachet to the Board of Directors. David Schlachet serves as a director of several public and private ... [Published EON Science - Apr 14 2014]
First reported Apr 14 2014 - Updated Apr 15 2014 - 2 reports

Syneron Receives US FDA Clearance to Market the UltraShape System for Fat Cell Destruction

/CNW/ - Syneron Medical Ltd. (NASDAQ:?ELOS), a global market leader in the aesthetic medical device marketplace, announced today that it has received the United States Food and Drug ... ... [Published Big News Network - Apr 14 2014]
First reported Apr 08 2014 - Updated Apr 09 2014 - 2 reports

Syneron Medical receives CE mark for treatment of striae and acne scars

Syneron Medical Ltd., an aesthetic device company, has received CE mark indication for its proprietary Sublative technology for the treatment of striae, or stretch marks, and acne scars. The new treatment protocols are now available on all of the Syneron ... [Published Individual.com - Apr 09 2014]
First reported Apr 04 2014 - Updated Apr 04 2014 - 3 reports

Synerons Innovative Products Featured at 34th ASLMS Annual Conference

/CNW/ - Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, announced today that the Syneron Candela's leading products will be featured in ... ... [Published Big News Network - Apr 04 2014]
First reported Apr 04 2014 - Updated Apr 04 2014 - 3 reports

Thoratec Slapped with Class I Recall for HeartMate Controller - Analyst Blog

Bad news for Thoratec Corporation (NASDAQ: THOR)! The U.S. Food and Drug Administration (FDA) slapped its highest level Class I warning on the company's recent recall of HeartMate II implantable heart pumps due to a problem with their Pocket System Controllers. ... [Published Benzinga.com - Apr 04 2014]
First reported Apr 03 2014 - Updated Apr 04 2014 - 2 reports

Syneron Sublative Technology Earns CE Mark for Stretch Mark and Acne Scar Treatment

-- /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ:ELOS), a leading global aesthetic device company, announced today that its proprietary Sublative™ technology has received CE Mark indication for the effective treatment of striae (stretch marks) and acne ... [Published Scoop Asia - Apr 04 2014]

Quotes

...significantly enhance not only its capital equipment sales but also the recurring revenue part of its business," stated Amit Meridor, Syneron's CEO. "We plan to limit the highly anticipated initial launch of UltraShape in the US in 2014 to a select list of key opinion leaders in aesthetic medicine. This initial launch phase will enable us to fully develop our recurring revenue part of the business which we plan to combine with account managers that will support the business needs of our customers. In parallel to the US effort we plan to gradually implement similar models in international markets, in which the lack of FDA clearance of the technology was a drawback to its growth. We expect to see the full impact of this effort in 2015" concluded Mr. Meridor
"The UltraShape technology is one of the two pillars of our body shaping strategy," said Syneron chairman Dr. Shimon Eckhouse . "Our significant investment in the development of non-invasive body shaping products puts us in a unique position to lead the market with UltraShape mechanical fat destruction technology, and with our unique VelaShape III elos based thermal technology. With these two FDA cleared technologies we have a wide range of body shaping indications including circumferential reduction in various body areas and reduction in cellulite appearance. These two complementary technologies will be key factors for serving our global customer base in the fast growing body shaping market."
"In parallel to the US effort we plan to gradually implement similar models in international markets, in which the lack of FDA clearance of the technology was a drawback to its growth. We expect to see the full impact of this effort in 2015" Meridor added
...value with its industry leading technologies and with prudent financial management," said Michael D West , Asterias' new Chief Executive Officer. "We also welcome our new shareholders who will receive Asterias Series A common stock when Geron Corporation completes its distribution of those shares to its stockholders. Asterias' management is continuing to evaluate the opportunities for Asterias' stem cell assets in order to select the best paths for the advancement of its key product programs, including paths that can be followed with Asterias' current financial assets and those that would be open to us if Asterias were to obtain the funding it is seeking in the form of research grants, cooperative development arrangements, and new equity capital" Dr. West concluded

More Content

All (109) | News (89) | Reports (0) | Blogs (10) | Audio/Video (0) | Fact Sheets (1) | Press Releases (9)
sort by: Date | Relevance
Syneron Receives US FDA Clearance to Market the... [Published Medianet - 1 hour ago]
Syneron Receives US FDA Clearance to Market the... [Published Asia Net - 1 hour ago]
Stock Analysts’ Downgrades for April, 23rd (ALS... [Published American Banking News - 6 hours ago]
YPF Sociedad Anonima Lowered to Underperform at... [Published Zolmax News - 7 hours ago]
Syneron Medical Stock Rating Lowered by Zacks (... [Published American Banking News - Stock Ratings - 7 hours ago]
Senvest Gains 5 Percent In March, Finds More Sh... [Published Value Walk - 8 hours ago]
ABIOMED Up on License from Opsens [Published Zacks.com - Apr 22 2014]
ABIOMED Up on License from Opsens [Published Yahoo! Finance - Apr 22 2014]
ABIOMED's Impella RP Bags CE Mark - Analyst Blog [Published Benzinga.com - Apr 18 2014]
ABIOMED's Impella RP Bags CE Mark [Published Yahoo! Finance - Apr 17 2014]
ABIOMED's Impella RP Bags CE Mark [Published Zacks.com - Apr 17 2014]
Syneron Medical's CEO Discusses FDA Clearance o... [Published Seeking Alpha - Apr 17 2014]
Syneron obtains FDA approval for UltraShape [Published HispanicBusiness.com - Apr 16 2014]
Accuray Upped to Buy [Published Yahoo! Finance - Apr 16 2014]
Syneron to Host Conference Call and Webcast to ... [Published Benzinga.com - Apr 16 2014]
Syneron Medical : to Host Conference Call and W... [Published 4 Traders - Apr 16 2014]
Syneron to Host Conference Call and Webcast to ... [Published PR Newswire: Policy & Public Interest - Apr 16 2014]
The New Wave in Covidien's Endoscopic Devices -... [Published Nasdaq - Apr 15 2014]
The New Wave in Covidien's Endoscopic Devices [Published Zacks.com - Apr 15 2014]
Syneron gets FDA 510(k) clearance for UltraShap... [Published Medical Devices Business Review - Apr 15 2014]
BIOTIME : Announces Board Membership Changes an... [Published 4 Traders - Apr 15 2014]
UltraShape Cleared for Fat Cell Destruction [Published Surgical Aesthetics Magazine - Apr 15 2014]
Balanced View of Luminex Corporation [Published Zacks.com - Apr 14 2014]
Syneron Receives US FDA Clearance to Market the... [Published Big News Network - Apr 14 2014]
Several Appointments Made at BioTime and Subsid... [Published ODT Mag - Apr 14 2014]
Varian Medical Systems Settles Patent Dispute [Published Zacks.com - Apr 14 2014]
Syneron Medical Ltd receives US FDA clearance t... [Published Reuters - Apr 14 2014]
Morning Market Movers [Published Benzinga.com - Apr 14 2014]
Syneron Gets FDA Clearance To Market UltraShape... [Published RTTNews.com - Apr 14 2014]
BioTime, Inc. Announces Board Membership Change... [Published Nasdaq - Apr 14 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Syneron to Host Conference Call and Webcast to ... [Published PR Newswire: Policy & Public Interest - Apr 16 2014]
IRVINE, Calif., April 16, 2014 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), a global market leader in the aesthetic medical device marketplace, announced today details for its previously announced conference call and webcast to discuss the ...
BioTime, Inc. Announces Board Membership Change... [Published EON Science - Apr 14 2014]
ALAMEDA, Calif.--(EON: Enhanced Online News)--BioTime, Inc. (NYSE MKT: BTX) announced that its Board of Directors has appointed Deborah Andrews and David Schlachet to the Board of Directors. David Schlachet serves as a director of several public and private ...
BioTime, Inc. Announces Board Membership Change... [Published Business Wire Science: Science News - Apr 14 2014]
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX) announced that its Board of Directors has appointed Deborah Andrews and David Schlachet to the Board of Directors. David Schlachet serves as a director of several public and private companies. ...
BioTime, Inc. Announces Board Membership Change... [Published Business Wire Health News - Apr 14 2014]
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX) announced that its Board of Directors has appointed Deborah Andrews and David Schlachet to the Board of Directors. David Schlachet serves as a director of several public and private companies. ...
PE-backed Z-Medica names new president and CEO [Published PE Hub Blog - Apr 03 2014]
Z-Medica , which is backed by DW Healthcare Partners , has hired Stephen J. Fanning as president and CEO. Previously, Fanning was the chairman, president and CEO of Solta Medical . Based in Wallingford, Conn., Z-Medical is a maker of blood clotting ...
1 2

Press Releases

sort by: Date | Relevance
Syneron Receives US FDA Clearance to Market the... [Published Financial Services - Apr 14 2014]
Syneron's Innovative Products Featured at 34th ... [Published Financial Services - Apr 04 2014]
Syneron Sublative Technology Earns CE Mark for ... [Published Financial Services - Apr 03 2014]
Syneron Reports Fourth Quarter and Full Year 20... [Published Financial Services - Feb 20 2014]
Syneron Medical Acquires New Star Lasers [Published Financial Services - Feb 20 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.